Kings Path Partners LLC Sells 13,100 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Kings Path Partners LLC lowered its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 38.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,815 shares of the medical equipment provider's stock after selling 13,100 shares during the quarter. Kings Path Partners LLC's holdings in BioLife Solutions were worth $475,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of BioLife Solutions by 13.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider's stock valued at $1,835,000 after acquiring an additional 8,258 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioLife Solutions in the fourth quarter valued at approximately $31,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions in the 4th quarter valued at $11,113,000. ProShare Advisors LLC bought a new position in BioLife Solutions in the 4th quarter valued at $282,000. Finally, Millennium Management LLC grew its stake in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares during the period. Institutional investors own 93.24% of the company's stock.

Insider Buying and Selling

In other news, CMO Todd Berard sold 8,902 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $201,719.32. Following the completion of the transaction, the chief marketing officer now directly owns 135,956 shares of the company's stock, valued at $3,080,762.96. This trade represents a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sarah Aebersold sold 1,091 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $27,275.00. Following the completion of the transaction, the insider now owns 58,816 shares of the company's stock, valued at approximately $1,470,400. This represents a 1.82% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,725 shares of company stock valued at $1,710,666. Company insiders own 2.20% of the company's stock.

BioLife Solutions Stock Performance

Shares of BLFS stock traded down $0.49 on Friday, hitting $21.83. 786,262 shares of the stock were exchanged, compared to its average volume of 389,684. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.04 billion, a PE ratio of -20.59 and a beta of 2.01. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55. The firm's 50 day moving average is $22.86 and its two-hundred day moving average is $25.07.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million during the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. Sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BLFS has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.17.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.